*The Blood Biomarkers of Asthma DOI: http://dx.doi.org/10.5772/intechopen.106807*

[14] Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O'Byrne PM, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. The Journal of Allergy and Clinical Immunology. 2016;**137**:7586

[15] Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for nonT2 asthma. Allergy. 2020;**75**:311325

[16] Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;**184**:25212522

[17] Jeong J, Lee HK. The role of CD4(+) T cells and microbiota in the pathogenesis of asthma. International Journal of Molecular Sciences. 2021;**22**:11822

[18] Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function. Annual Review of Immunology. 2012;**30**:531564

[19] Mamessier E, Nieves A, Lorec AM, Dupuy P, Pinot D, Pinet C, et al. Tcell activation during exacerbations: A longitudinal study in refractory asthma. Allergy. 2008;**63**:12021210

[20] Saradna A, Do DC, Kumar S, Fu QL, Gao P. Macrophage polarization and allergic asthma. Translational Research. 2018;**191**:114

[21] Fitzpatrick AM, Holguin F, Teague WG, Brown LA. Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma. Journal of Allergy and Clinical Immunology. 2008;**121**:1378

[22] Gloudemans AK, Lambrecht BN, Smits HH. Potential of immunoglobulin A to prevent allergic asthma. Clinical & Developmental Immunology. 2013;**2013**:542091

[23] Ludviksson BR, Eiriksson TH, Ardal B, Sigfusson A, Valdimarsson H. Correlation between serum immunoglobulin A concentrations and allergic manifestations in infants. The Journal of Pediatrics. 1992;**121**:2327

[24] Balzar S, Strand M, Nakano T, Wenzel SE. Subtle immunodeficiency in severe asthma: IgA and IgG2 correlate with lung function and symptoms. International Archives of Allergy and Immunology. 2006;**140**:96102

[25] Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al. Asthma outcomes: Biomarkers. The Journal of Allergy and Clinical Immunology. 2012;**129**:S9S23

[26] Holt PG, Strickland D, Bosco A, Belgrave D, Hales B, Simpson A, et al. Distinguishing benign from pathologic TH2 immunity in atopic children. The Journal of Allergy and Clinical Immunology. 2016;**137**:379387

[27] Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nature Reviews. Drug Discovery. 2016;**15**:3550

[28] Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin4 (IL4) and IL13 production. Cytokine. 2015;**75**:1424

[29] Swain SL, Weinberg AD, English M, Huston G. IL4 directs the development of Th2like helper effectors. Journal of Immunology. 1990;**145**:37963806

[30] Coyle AJ, Le Gros G, Bertrand C, Tsuyuki S, Heusser CH, Kopf M, et al. Interleukin4 is required for the induction of lung Th2 mucosal immunity. American Journal of

Respiratory Cell and Molecular Biology. 1995;**13**:5459

[31] Venkayya R, Lam M, Willkom M, Grunig G, Corry DB, Erle DJ. The Th2 lymphocyte products IL4 and IL13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. American Journal of Respiratory Cell and Molecular Biology. 2002;**26**:202208

[32] Stirling RG, van Rensen EL, Barnes PJ, Chung KF. Interleukin5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. American Journal of Respiratory and Critical Care Medicine. 2001;**164**:14031409

[33] Shi H, Qin S, Huang G, Chen Y, Xiao C, Xu H, et al. Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. American Journal of Respiratory Cell and Molecular Biology. 1997;**16**:220224

[34] Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant TH2 like bronchoalveolar Tlymphocyte population in atopic asthma. The New England Journal of Medicine. 1992;**326**:298304

[35] Ohnishi T, Kita H, Weiler D, Sur S, Sedgwick JB, Calhoun WJ, et al. IL5 is the predominant eosinophilactive cytokine in the antigeninduced pulmonary latephase reaction. The American Review of Respiratory Disease. 1993;**147**:901907

[36] Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al. Interleukin 13 induces interleukin 4independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proceedings of the National Academy of Sciences of the United States of America. 1993;**90**:37303734

[37] Hunninghake GM, SotoQuiros ME, Avila L, Su J, Murphy A, Demeo DL, et al. Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood. The Journal of Allergy and Clinical Immunology. 2007;**120**:8490

[38] Corren J. Role of interleukin13 in asthma. Current Allergy and Asthma Reports. 2013;**13**:415420

[39] Lee YC, Lee KH, Lee HB, Rhee YK. Serum levels of interleukins (IL)4, IL5, IL13, and interferongamma in acute asthma. The Journal of Asthma. 2001;**38**:665671

[40] Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderatetosevere uncontrolled asthma. The New England Journal of Medicine. 2018;**378**:24862496

[41] Eger K, Kroes JA, Ten BA, Bel EH. Longterm therapy response to AntiIL5 biologics in severe asthma: A reallife evaluation. The Journal of Allergy and Clinical Immunology. In Practice. 2021;**9**:11941200

[42] Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewicz M, Yao L, et al. IL31 is associated with cutaneous lymphocyte antigenpositive skin homing T cells in patients with atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2006;**117**:418425

[43] Yu JI, Han WC, Yun KJ, Moon HB, Oh GJ, Chae SC. Identifying polymorphisms in IL31 and their association with susceptibility to asthma. Korean Journal of Pathology. 2012;**46**:162168

*The Blood Biomarkers of Asthma DOI: http://dx.doi.org/10.5772/intechopen.106807*

[44] Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin31: The "itchy" cytokine in inflammation and therapy. Allergy. 2021;**76**:29822997

[45] Lai T, Wu D, Li W, Chen M, Yi Z, Huang D, et al. Interleukin31 expression and relation to disease severity in human asthma. Scientific Reports. 2016;**6**:22835

[46] Ramakrishnan RK, Al HS, Hamid Q. Role of IL17 in asthma pathogenesis and its implications for the clinic. Expert Review of Respiratory Medicine. 2019;**13**:10571068

[47] Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, et al. IL17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. The Journal of Allergy and Clinical Immunology. 2001;**108**:430438

[48] Zhao Y, Yang J, Gao YD, Guo W. Th17 immunity in patients with allergic asthma. International Archives of Allergy and Immunology. 2010;**151**:297307

[49] Sehra S, Yao W, Nguyen ET, GlossonByers NL, Akhtar N, Zhou B, et al. TH9 cells are required for tissue mast cell accumulation during allergic inflammation. The Journal of Allergy and Clinical Immunology. 2015;**136**:433440

[50] Jia L, Wang Y, Li J, Li S, Zhang Y, Shen J, et al. Detection of IL9 producing T cells in the PBMCs of allergic asthmatic patients. BMC Immunology. 2017;**18**:38

[51] Louahed J, Toda M, Jen J, Hamid Q, Renauld JC, Levitt RC, et al. Interleukin9 upregulates mucus expression in the airways. American Journal of Respiratory Cell and Molecular Biology. 2000;**22**:649656

[52] Hoppenot D, Malakauskas K, Lavinskiene S, Bajoriuniene I,

Kalinauskaite V, Sakalauskas R. Peripheral blood Th9 cells and eosinophil apoptosis in asthma patients. Medicina (Kaunas, Lithuania). 2015;**51**:1017

[53] Mitchell PD, O'Byrne PM. Epithelialderived cytokines in asthma. Chest. 2017;**151**:13381344

[54] Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL25 augments type 2 immune responses by enhancing the expansion and functions of TSLPDCactivated Th2 memory cells. The Journal of Experimental Medicine. 2007;**204**:18371847

[55] Angkasekwinai P, Park H, Wang YH, Wang YH, Chang SH, Corry DB, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. The Journal of Experimental Medicine. 2007;**204**:15091517

[56] Cheng D, Xue Z, Yi L, Shi H, Zhang K, Huo X, et al. Epithelial interleukin25 is a key mediator in Th2high, corticosteroidresponsive asthma. American Journal of Respiratory and Critical Care Medicine. 2014;**190**:639648

[57] ElHusseini ZW, Gosens R, Dekker F, Koppelman GH. The genetics of asthma and the promise of genomicsguided drug target discovery. The Lancet Respiratory Medicine. 2020;**8**:10451056

[58] Saikumar JA, Hesse L, Ketelaar ME, Koppelman GH, Nawijn MC. The central role of IL33/IL1RL1 pathway in asthma: From pathogenesis to intervention. Pharmacology & Therapeutics. 2021;**225**:107847

[59] Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL33, an interleukin1like cytokine that signals via the IL1

receptorrelated protein ST2 and induces T helper type 2associated cytokines. Immunity. 2005;**23**:479490

[60] Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2IL33 pathway. American Journal of Respiratory and Critical Care Medicine. 2009;**179**:772781

[61] Bhowmik M, Majumdar S, Dasgupta A, Gupta BS, Saha S. Pilotscale study of human plasma proteomics identifies ApoE and IL33 as markers in atopic asthma. Journal of Asthma Allergy. 2019;**12**:273283

[62] West EE, Kashyap M, Leonard WJ. TSLP: A key regulator of asthma pathogenesis. Drug Discovery Today Diseases Mechanism. 2012;**9**:e83e88

[63] Salter BM, Oliveria JP, Nusca G, Smith SG, Tworek D, Mitchell PD, et al. IL25 and IL33 induce Type 2 inflammation in basophils from subjects with allergic asthma. Respiratory Research. 2016;**17**:5

[64] Diver S, Khalfaoui L, Emson C, Wenzel SE, MenziesGow A, Wechsler ME, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderatetosevere uncontrolled asthma (CASCADE): A doubleblind, randomised, placebocontrolled, phase 2 trial. The Lancet Respiratory Medicine. 2021;**9**:12991312

[65] Lloyd CM, Delaney T, Nguyen T, Tian J, MartinezA C, Coyle AJ, et al. CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocytederived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo.

The Journal of Experimental Medicine. 2000;**191**:265274

[66] Nakamura H, Weiss ST, Israel E, Luster AD, Drazen JM, Lilly CM. Eotaxin and impaired lung function in asthma. American Journal of Respiratory and Critical Care Medicine. 1999;**160**:19521956

[67] Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood. 2000;**95**:30323043

[68] Robays LJ, Maes T, Lebecque S, Lira SA, Kuziel WA, Brusselle GG, et al. Chemokine receptor CCR2 but not CCR5 or CCR6 mediates the increase in pulmonary dendritic cells during allergic airway inflammation. Journal of Immunology. 2007;**178**:53055311

[69] AlRashoudi R,

Moir G, AlHajjaj MS, AlAlwan MM, Wilson HM, Crane IJ. Differential expression of CCR2 and CX3CR1 on CD16(+) monocyte subsets is associated with asthma severity. Allergy, Asthma and Clinical Immunology. 2019;**15**:64

[70] Wang A, Wang Z, Cao Y, Cheng S, Chen H, Bunjhoo H, et al. CCL2/CCR2 dependent recruitment of Th17 cells but not Tc17 cells to the lung in a murine asthma model. International Archives of Allergy and Immunology. 2015;**166**:5262

[71] Mellado M, Martin DAA, Gomez L, Martinez C, Rodriguez-Frade JM. Chemokine receptor 2 blockade prevents asthma in a cynomolgus monkey model. The Journal of Pharmacology and Experimental Therapeutics. 2008;**324**:769775

[72] Pease JE, Williams TJ. Eotaxin and asthma. Current Opinion in Pharmacology. 2001;**1**:248253

*The Blood Biomarkers of Asthma DOI: http://dx.doi.org/10.5772/intechopen.106807*

[73] Li X, Wang B, Huang M, Wang X. miR30a3p participates in the development of asthma by targeting CCR3. Open Medicine. 2020;**15**:483491

[74] Lun SW, Wong CK, Ko FW, Ip WK, Hui DS, Lam CW. Aberrant expression of CC and CXC chemokines and their receptors in patients with asthma. Journal of Clinical Immunology. 2006;**26**:145152

[75] Grozdanovic M,

Laffey KG, Abdelkarim H, Hitchinson B, Harijith A, Moon HG, et al. Novel peptide nanoparticlebiased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness. The Journal of Allergy and Clinical Immunology. 2019;**143**:669680

[76] Schuh JM, Blease K, Hogaboam CM. The role of CC chemokine receptor 5 (CCR5) and RANTES/CCL5 during chronic fungal asthma in mice. The FASEB Journal. 2002;**16**:228230

[77] RojasDotor S,

SeguraMendez NH, MiyaguiNamikawa K, MondragonGonzalez R. Expression of resistin, CXCR3, IP10, CCR5 and MIP-1alpha in obese patients with different severity of asthma. Biological Research. 2013;**46**:1320

[78] Gauthier M, Kale SL, Oriss TB, Scholl K, Das S, Yuan H, et al. Dual role for CXCR3 and CCR5 in asthmatic type 1 inflammation. The Journal of Allergy and Clinical Immunology. 2022;**149**:113124

[79] Saeki H, Tamaki K. Thymus and activation regulated chemokine (TARC)/ CCL17 and skin diseases. Journal of Dermatological Science. 2006;**43**:7584

[80] Luu QQ, Moon JY, Lee DH, Ban GY, Kim SH, Park HS. Role of thymus and activationregulated chemokine in

allergic asthma. Journal of Asthma Allergy. 2022;**15**:157167

[81] Leung TF, Wong CK, Chan IH, Ip WK, Lam CW, Wong GW. Plasma concentration of thymus and activationregulated chemokine is elevated in childhood asthma. The Journal of Allergy and Clinical Immunology. 2002;**110**:404409

[82] Leung TF, Wong CK, Lam CW, Li AM, Ip WK, Wong GW, et al. Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children. The European Respiratory Journal. 2003;**21**:616620

[83] Kalayci O, Sonna LA, Woodruff PG, Camargo CJ, Luster AD, Lilly CM. Monocyte chemotactic protein4 (MCP-4; CCL13): A biomarker of asthma. The Journal of Asthma. 2004;**41**:2733

[84] Soliman NA, Abdel GM, El KR, Hafez YM, Abo ER, Atef MM. Cross talk between Hsp72, HMGB1 and RAGE/ ERK1/2 signaling in the pathogenesis of bronchial asthma in obese patients. Molecular Biology Reports. 2020;**47**:41094116

[85] Jiang XG, Yang XD, Lv Z, Zhuang PH. Elevated serum levels of TNFalpha, IL8, and ECP can be involved in the development and progression of bronchial asthma. The Journal of Asthma. 2018;**55**:111118

[86] Rydell N, Nagao M, Moverare R, Ekoff H, Sjolander A, Borres MP, et al. Serum eosinophilic cationic protein is a reliable biomarker for childhood asthma. International Archives of Allergy and Immunology. 2022;**183**:744752

[87] Refaat MM, El SE, Abd EW, Elbanna AH, Sayed H. Relationship between sputum periostin level and inflammatory asthma phenotypes in Egyptian patients. The Journal of Asthma. 2021;**58**:12851291

[88] Hwang YH, Lee Y, Paik MJ, Yee ST. Inhibitions of HMGB1 and TLR4 alleviate DINPinduced asthma in mice. Toxicological Research (Camb). 2019;**8**:621629

[89] Baos S, Calzada D, Cremades L, Sastre J, Quiralte J, Florido F, et al. Biomarkers associated with disease severity in allergic and nonallergic asthma. Molecular Immunology. 2017;**82**:3445

[90] Yildiz H, Alp HH, Sunnetcioglu A, Ekin S, Mermit CB. Evaluation serum levels of YKL40, Periostin, and some inflammatory cytokines together with IL37, a new antiinflammatory cytokine, in patients with stable and exacerbated asthma. Heart & Lung. 2021;**50**:177183

[91] Zhou T, Huang X, Ma J, Zhou Y, Liu Y, Xiao L, et al. Association of plasma soluble CD14 level with asthma severity in adults: A case control study in China. Respiratory Research. 2019;**20**:19

[92] Ogino K, Obase Y, Takahashi N, Shimizu H, Takigawa T, Wang DH, et al. High serum arginase I levels in asthma: Its correlation with highsensitivity Creactive protein. The Journal of Asthma. 2011;**48**:17

[93] Ma SL, Zhang L. Elevated serum OX40L is a biomarker for identifying corticosteroid resistance in pediatric asthmatic patients. BMC Pulmonary Medicine. 2019;**19**:66

[94] Specjalski K, Niedoszytko M. MicroRNAs: Future biomarkers and targets of therapy in asthma? Current Opinion in Pulmonary Medicine. 2020;**26**:285292

[95] Rial MJ, Canas JA, RodrigoMunoz JM, ValverdeMonge M, Sastre B, Sastre J, et al. Changes in serum MicroRNAs after AntiIL5 biological treatment of severe asthma. International Journal of Molecular Sciences. 2021;**22**:19

[96] ElKashef S, Ahmad SE, Soliman Y, Mostafa MS. Role of microRNA21 and microRNA155 as biomarkers for bronchial asthma. Innate Immunity. 2021;**27**:6169

[97] Yu Y, Men S, Zhang Y. miR20a5p ameliorates ovalbumin (OVA)induced mouse model of allergic asthma through targeting ATG7regulated cell death, fibrosis and inflammation. International Immunopharmacology. 2021;**95**:107342

[98] Trifunovic A, Dombkowski A, Cukovic D, Mahajan P. The potential of microRNAs as noninvasive biomarkers in acute pediatric asthma. The Journal of Allergy and Clinical Immunology. 2020;**145**:17061708

[99] Tiwari A, Li J, Kho AT, Sun M, Lu Q, Weiss ST, et al. COPDassociated miR-1455p is downregulated in earlydecline FEV1 trajectories in childhood asthma. The Journal of Allergy and Clinical Immunology. 2021;**147**:21812190

[100] Li X, Ye S, Lu Y. Long noncoding RNA NEAT1 overexpression associates with increased exacerbation risk, severity, and inflammation, as well as decreased lung function through the interaction with microRNA124 in asthma. Journal of Clinical Laboratory Analysis. 2020;**34**:e23023

[101] Weidner J, Ekerljung L, Malmhall C, Miron N, Radinger M. Circulating microRNAs correlate to clinical parameters in individuals with allergic and nonallergic asthma. Respiratory Research. 2020;**21**:107

*The Blood Biomarkers of Asthma DOI: http://dx.doi.org/10.5772/intechopen.106807*

[102] Rostami HS, Alizadeh Z, Mazinani M, Mahlooji RM, Fazlollahi MR, Kazemnejad A, et al. Exosomal MicroRNAs as Biomarkers in Allergic Asthma. Iranian Journal of Allergy, Asthma, and Immunology. 2021;**20**:160168

[103] Zhang D, Wu Y, Sun G. miR192 suppresses T follicular helper cell differentiation by targeting CXCR5 in childhood asthma. Scandinavian Journal of Clinical and Laboratory Investigation. 2018;**78**:236242

[104] Wu C, Xu K, Wang Z, Chen Z, Sun Z, Yu W, et al. A novel microRNA miR11653p as a potential diagnostic biomarker for allergic asthma. Biomarkers. 2019;**24**:5663

[105] Wang W, Wang J, Chen H, Zhang X, Han K. Downregulation of miR3934 in peripheral blood mononuclear cells of asthmatic patients and its potential diagnostic value. BioMed Research International. 2021;**2021**:8888280

[106] Xu L, Yi M, Tan Y, Yi Z, Zhang Y. A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma. Therapeutic Advances in Respiratory Disease. 2020;**14**:1022250393

[107] Tian M, Ji Y, Wang T, Zhang W, Zhou Y, Cui Y. Changes in circulating microRNA126 levels are associated with immune imbalance in children with acute asthma. International Journal of Immunopathology and Pharmacology. 2018;**32**:1680016491

[108] Dai B, Sun F, Cai X, Li C, Liu F, Shang Y. Long noncoding RNA PTTG3P/ miR1923p/CCNB1 axis is a potential biomarker of childhood asthma. International Immunopharmacology. 2021;**101**:108229

[109] Ye S, Zhu S, Feng L. LncRNA ANRIL/miR125a axis exhibits potential as a biomarker for disease exacerbation, severity, and inflammation in bronchial asthma. Journal of Clinical Laboratory Analysis. 2020;**34**:e23092

[110] Wu D, Gu B, Qian Y, Sun Y, Chen Y, Mao ZD, et al. Long noncoding RNA growth arrest specific5: A potential biomarker for early diagnosis of severe asthma. Journal of Thoracic Disease. 2020;**12**:19601971

[111] Qiu YY, Wu Y, Lin MJ, Bian T, Xiao YL, Qin C. LncRNAMEG3 functions as a competing endogenous RNA to regulate Treg/Th17 balance in patients with asthma by targeting microRNA17/ RORgammat. Biomedicine & Pharmacotherapy. 2019;**111**:386394

[112] Xia L, Wang X, Liu L, Fu J, Xiao W, Liang Q, et al. lncBAZ2B promotes M2 macrophage activation and inflammation in children with asthma through stabilizing BAZ2B premRNA. The Journal of Allergy and Clinical Immunology. 2021;**147**:921932
